Study findings updated . AI-assisted evidence summary, not individual medical advice or a clinician endorsement.
THE SHORT VERSION
What’s worth knowing.
The key findings, what they mean, and the context that matters.
THE HEADLINE TAKEAWAY1 in 5 needed the ICUOf babies under 6 months hospitalized with COVID, not counting birth stays
Young infants have COVID hospital rates rivaling older adults, often needing ICU.
From October 2022 to April 2024, CDC surveillance counted 1,470 COVID hospital stays among US babies under 6 months, who are too young for vaccines. Their hospitalization rates topped every other age group except adults 75 and older. Of babies hospitalized after their birth stay, 22.1% went to intensive care and nine died.
Many parents think COVID is mild for every child. For the youngest babies, the hospital risk looks more like a grandparent's, and these infants depend on protection from others, including antibodies passed on during pregnancy. This surveillance covers selected US counties and counts only hospitalized babies, so it cannot show how often infected infants overall become seriously ill.
See the evidence
CDC's COVID-NET hospital surveillance in selected counties of 12 states, with chart reviews of 1,148 babies under 6 months hospitalized with COVID from October 2022 to April 2024.
From the study: “During October 2022-April 2024, COVID-NET identified 1,470 COVID-19-associated hospitalizations among infants aged <6 months.”
1 in 5 needed the ICU
Havers FP et al. COVID-19-Associated Hospitalizations and Maternal Vaccination Among Infants Aged <6 Months - COVID-NET, 12 States, October 2022-April 2024. MMWR. Morbidity and mortality weekly report. 2024.
From the study: “COVID-19-associated hospitalization rates among young infants were higher than rates among any other age group, except adults aged ≥75 years”
1 in 5 needed the ICU
Havers FP et al. COVID-19-Associated Hospitalizations and Maternal Vaccination Among Infants Aged <6 Months - COVID-NET, 12 States, October 2022-April 2024. MMWR. Morbidity and mortality weekly report. 2024.
COVID-19 became a top-10 cause of death for US kids.
821 deaths in 1 yearUS deaths at ages 0-19 with COVID as the underlying cause, Aug 2021 to Jul 2022
From August 2021 to July 2022, COVID-19 was the underlying cause of 821 deaths among Americans aged 0 to 19. Measured against the usual causes of death at these ages, that placed COVID among the 10 leading causes, and first among infectious and respiratory illnesses, ahead of flu and pneumonia.
Child deaths from COVID were rare, but the virus killed more young Americans in a year than any vaccine-preventable disease did each year in the era just before its vaccine arrived. The count covers the large Delta and Omicron waves, when few children had prior immunity, so yearly tolls today may differ.
See the evidence
A national cross-sectional analysis of CDC death-certificate data comparing COVID-19 deaths among US 0- to 19-year-olds from August 2021 to July 2022 with leading causes of death in 2019.
From the study: “with at least 821 CYP deaths occurring in the 1-year period from August 1, 2021, to July 31, 2022”
821 deaths in 1 year
Flaxman S et al. Assessment of COVID-19 as the Underlying Cause of Death Among Children and Young People Aged 0 to 19 Years in the US. JAMA network open. 2023.
From the study: “COVID-19 mortality in the time period of August 1, 2021, to July 31, 2022, was among the 10 leading causes of death in CYP aged 0 to 19 years in the US”
821 deaths in 1 year
Flaxman S et al. Assessment of COVID-19 as the Underlying Cause of Death Among Children and Young People Aged 0 to 19 Years in the US. JAMA network open. 2023.
From the study: “Considering infectious and respiratory diseases only, COVID-19 ranked as the top (first) cause of death in US CYP”
821 deaths in 1 year
Flaxman S et al. Assessment of COVID-19 as the Underlying Cause of Death Among Children and Young People Aged 0 to 19 Years in the US. JAMA network open. 2023.
Vaccination during pregnancy was linked to fewer COVID hospital stays for babies.
52% lower hospital riskVaccine effectiveness: mom's shot in pregnancy vs. baby's COVID hospital stay
Babies under 6 months were less likely to be hospitalized with COVID if their mothers were fully vaccinated with an mRNA vaccine during pregnancy, compared with babies of unvaccinated mothers. Estimated protection was 52% overall and 69% when the mother's vaccination came after 20 weeks of pregnancy.
Babies this young cannot get COVID vaccines themselves, so antibodies passed across the placenta are their main shield. The study also found protection against intensive care admission. This case-control study cannot fully rule out other differences between families, and estimated protection fell to 38% once Omicron dominated.
See the evidence
A CDC-funded case-control study of 537 babies hospitalized with COVID and 512 hospitalized for other reasons at 30 hospitals in 22 states, July 2021 to March 2022.
From the study: “hospitalization among infants younger than 6 months of age was 52% (95% confidence interval [CI], 33 to 65)”
52% lower hospital risk
Halasa NB et al. Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants. The New England journal of medicine. 2022.
From the study: “the risk was reduced by 80% (95% CI, 60 to 90) during the period of circulation of the delta variant and by 38% (95% CI, 8 to 58) during circulation of the omicron variant”
52% lower hospital risk
Halasa NB et al. Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants. The New England journal of medicine. 2022.
Teen boys had more heart complications after COVID than after vaccination.
At least 1.8× higherRisk ratio for heart complications, infection vs. second vaccine dose, boys 12-17
CDC researchers compared heart inflammation (myocarditis or pericarditis) after COVID infection with that after mRNA vaccination. Vaccine-linked cases were most common in males aged 12-17 after the second dose. Yet in that same group, cardiac complications were 1.8 to 5.6 times as common after infection as after the second dose.
Heart inflammation after vaccination is real and is seen most in teen boys. This study puts it beside the alternative: catching COVID carried a higher heart risk in the very group most affected by the vaccine. Cases came from diagnosis codes, and infections missed by testing would make infection look riskier than it truly is.
See the evidence
A CDC analysis of electronic health records from 40 US health systems covering more than 15 million people aged 5 and older, January 2021 to January 2022.
From the study: “The incidence of cardiac outcomes after mRNA COVID-19 vaccination was highest for males aged 12-17 years after the second vaccine dose”
At least 1.8× higher
Block JP et al. Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022. MMWR. Morbidity and mortality weekly report. 2022.
From the study: “within this demographic group, the risk for cardiac outcomes was 1.8-5.6 times as high after SARS-CoV-2 infection than after the second vaccine dose”
At least 1.8× higher
Block JP et al. Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022. MMWR. Morbidity and mortality weekly report. 2022.
About 4% of infected children developed long COVID in US health records.
1 in 25 childrenShare of infected US children with probable long COVID in health-record networks
In three large US health-record networks, 4% of children with a documented COVID infection were flagged with probable long COVID, compared with 10%-26% of adults. Measured against children who tested negative or were seen before the pandemic, the extra risk linked to infection was 1.5% in children and 5% to 6% in adults.
Long COVID is real in children but rarer than early surveys suggested, and far rarer than in adults. Still, even 1.5% of the millions of US children who have been infected adds up to a lot of kids. Counts rely on symptoms and diagnoses recorded in medical charts, so mild cases that never reached a doctor are likely missed.
See the evidence
A retrospective study of electronic health records from three national research networks in the NIH RECOVER Initiative, comparing infected patients with COVID-negative and pre-pandemic controls.
From the study: “Overall, 4% of children and 10%-26% of adults developed long COVID, depending on computable phenotype used.”
1 in 25 children
Mandel H et al. Long COVID Incidence Proportion in Adults and Children Between 2020 and 2024: An Electronic Health Record-Based Study From the RECOVER Initiative. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2025.
From the study: “Excess incidence among SARS-CoV-2 patients was 1.5% in children and ranged from 5% to 6% among adults, representing a lower-bound incidence estimation based on our control groups.”
1 in 25 children
Mandel H et al. Long COVID Incidence Proportion in Adults and Children Between 2020 and 2024: An Electronic Health Record-Based Study From the RECOVER Initiative. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2025.
Most teens meeting long COVID criteria at 3 months later improved.
1 in 14 still unwellYoung people meeting long COVID criteria at every check through 24 months
In an English study of young people who tested positive for COVID, 25% met a research definition of long COVID (called post-COVID condition) 3 months after infection. Only 7% (68 of 943) still met it at every check through 24 months. Girls and those with asthma, allergies or learning difficulties were more likely to stay unwell.
For families facing long COVID, the usual path is improvement, not permanent illness. A small group stays affected for years, and knowing who is at higher risk could help doctors offer support earlier. Only a small share of invited young people responded, and all were infected with early variants, so results may not match Omicron-era infections.
See the evidence
The CLoCk study followed English 11- to 17-year-olds who tested PCR-positive from September 2020 to March 2021 with questionnaires up to 24 months; 943 had data at every time point.
From the study: “While 25% (233/943) of CYP met the research definition of PCC at 3 months post-infection, only 7% (68/943) continued to meet the PCC definition persistently to 24 months”
1 in 14 still unwell
Nugawela MD et al. Predicting post-COVID-19 condition in children and young people up to 24 months after a positive SARS-CoV-2 PCR-test: the CLoCk study. BMC medicine. 2024.
From the study: “the data show that many CYP who initially meet the research definition of PCC get better over time”
1 in 14 still unwell
Nugawela MD et al. Predicting post-COVID-19 condition in children and young people up to 24 months after a positive SARS-CoV-2 PCR-test: the CLoCk study. BMC medicine. 2024.
From the study: “female sex, history of asthma, allergy problems, learning difficulties at school and family history of ongoing COVID-19 problems all predicted persistent PCC”
1 in 14 still unwell
Nugawela MD et al. Predicting post-COVID-19 condition in children and young people up to 24 months after a positive SARS-CoV-2 PCR-test: the CLoCk study. BMC medicine. 2024.
MIS-C, a rare post-COVID inflammatory illness, became far rarer with Omicron.
95% lower MIS-C riskMIS-C rate per confirmed infection, Omicron vs. earlier waves (rate ratio), England
MIS-C (multisystem inflammatory syndrome in children) is a severe inflammatory reaction that can strike weeks after a mild infection, often affecting the heart. In southeast England, the MIS-C rate per confirmed infection among children aged 0-16 was 95% lower in the Omicron period than in earlier waves.
MIS-C was one of the most feared child outcomes early in the pandemic. Its steep drop with newer variants and wider immunity means it is now rare, though sporadic cases still occur. This is a regional English analysis, and changes in testing could shift the count of confirmed infections used to calculate the rate.
See the evidence
A surveillance analysis of MIS-C cases and confirmed infections among children up to age 16 in southeast England across the pre-Delta, Delta and Omicron periods.
From the study: “In southeast England, MIS-C rates per confirmed SARS-CoV-2 infections in children aged 0-16 years were 56% lower”
95% lower MIS-C risk
Cohen JM et al. Lower Risk of Multisystem Inflammatory Syndrome in Children With the Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023.
From the study: “95% lower (RR, 0.05 [95% CI, .02-.10]) during the Omicron period”
95% lower MIS-C risk
Cohen JM et al. Lower Risk of Multisystem Inflammatory Syndrome in Children With the Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023.
Updated COVID shots were linked to fewer ER visits in young children.
76% fewer ER visitsVaccine effectiveness against COVID ER or urgent care visits, ages 9 months to 4 years
Among US children aged 9 months to 4 years, the updated COVID vaccine was estimated to be 76% effective at preventing COVID emergency or urgent care visits in the first 179 days after the shot, compared with children who skipped that season's dose. For ages 5-17, the estimate was 56%.
In the season before this study, COVID hospitalization rates were 600 per 100,000 for US babies under 6 months versus 21 per 100,000 for ages 5-17, so the youngest children remain at highest risk. Few children got the updated shot, and this observational design cannot fully rule out differences between families who vaccinate and those who do not.
See the evidence
A CDC test-negative study of more than 98,000 emergency and urgent care visits by children in a nine-state health-record network, August 2024 to September 2025.
From the study: “Among children aged 9 months-4 years, VE against COVID-19-associated ED/UC visits was estimated at 76% (95% CI = 58%-87%) during the first 7-179 days after vaccination.”
76% fewer ER visits
Irving SA et al. Effectiveness of 2024-2025 COVID-19 Vaccines in Children in the United States - VISION, August 29, 2024-September 2, 2025. MMWR. Morbidity and mortality weekly report. 2025.
From the study: “Among children and adolescents aged 5-17 years, VE against COVID-19-associated ED/UC visits was an estimated 56% (95% CI = 35%-70%) during the first 7-179 days after vaccination.”
76% fewer ER visits
Irving SA et al. Effectiveness of 2024-2025 COVID-19 Vaccines in Children in the United States - VISION, August 29, 2024-September 2, 2025. MMWR. Morbidity and mortality weekly report. 2025.
From the study: “ranging from 600 per 100,000 children aged <6 months to 21 per 100,000 children and adolescents aged 5-17 years”
76% fewer ER visits
Irving SA et al. Effectiveness of 2024-2025 COVID-19 Vaccines in Children in the United States - VISION, August 29, 2024-September 2, 2025. MMWR. Morbidity and mortality weekly report. 2025.
English records counted Long COVID consultations in children and young people
140.3 per 100,000 child-years
In England in 2022, recorded primary-care consultations for Long COVID in children and young people occurred at a rate of 140.3 per 100,000 child-years.
Child-years combine the children’s time observed. This observational rate uses consultation codes; it is not the percentage with the condition. It misses hospital or specialist care and self-reported cases. Recognition and recording practices may affect it.
Study details & original results
Raveendran, Vishnuga et al.. Trends in long COVID and post-viral fatigue in children in primary care in England.. BJGP open. 2026.
Recorded primary-care consultation rate for long COVID among children and young people in England in 2022
Lasting symptoms showed no clear overall difference across three viruses
At 4-6 weeks, clinicians recorded lasting symptoms in 24.0% after RSV, 22.0% after SARS-CoV-2 and 21.2% after influenza. No clear overall difference was established.
Researchers looked back at a group of children with lab-confirmed infection. Symptoms were most common after RSV in infants and after SARS-CoV-2 in school-aged children. No clear overall difference does not prove the groups were equal.
Age and features of the original illness were linked to lasting symptoms
Hospitalization and age over 6 years were linked to lasting symptoms after SARS-CoV-2 infection. Low blood oxygen was linked to lasting symptoms after RSV.
The comparison groups for these odds estimates are not given here, so the numerical comparisons are omitted.
Study details & original results
Bedir, Firat et al.. Post-acute symptom persistence following SARS-CoV-2, RSV, and influenza in children: A retrospective cohort study.. Medicine. 2026.
Clinician-documented persistent symptoms 4-6 weeks after PCR-confirmed infection in children; overall prevalence did not differ significantly among the three viruses.
Significant virus-by-age interaction in post-acute symptom persistence, with the highest prevalence after RSV among infants and after SARS-CoV-2 among school-aged children.
An additional respiratory virus did not clearly mean more severe COVID-19
Among hospitalized children at centers that systematically tested for multiple respiratory viruses, infection with another respiratory virus alongside COVID-19 was not clearly linked to higher odds of severe COVID-19.
The uncertainty range included no difference, and the comparison group is not given here. This does not prove equal outcomes.
Study details & original results
Di Chiara, Costanza et al.. SARS-CoV-2 Coinfections and Severity in Hospitalized Children With Systematic Testing.. The Pediatric infectious disease journal. 2026.
Respiratory viral coinfection was not associated with increased odds of severe COVID-19 among hospitalized children at centers with systematic multiplex PCR testing.
Hospital outcomes during the infection varied by virus and period
Among influenza hospital admissions, 10.5% entered intensive care pre-COVID and 11.8% during COVID. For SARS-CoV-2 admissions, the figure ranged from 5.0%-10.3% across variant periods.
Nationwide Swiss monitoring tracked hospitalized children younger than 18 years going forward. They had lab-confirmed influenza or SARS-CoV-2. A specific pneumonia type, lobar pneumonia, reached up to 20% in one influenza-period estimate.
Study details & original results
Zimmermann, Petra et al.. Comparison of Epidemiology, Risk Factors, Clinical Presentation and Outcomes of COVID-19 and Seasonal Influenza Among Hospitalized Swiss Children: A Nationwide Prospective Surveillance Study.. The Pediatric infectious disease journal. 2026.
ICU admission among Swiss children younger than 18 years hospitalized with laboratory-confirmed influenza or SARS-CoV-2 infection
Influenza: 10.5% pre-COVID and 11.8% during COVID; SARS-CoV-2: 5.0%-10.3% across variant periods (P = 0.001)
Lobar pneumonia among hospitalized children with influenza; the abstract reports only an upper period-specific proportion and states that overall complications were more frequent with influenza (P < 0.001)
Long COVID estimates varied by definition; the vaccine result was uncertain
A review estimated Long COVID in 18.1% across 52 groups of children, ranging from 16.2% to 21.6% by definition. At least one anti-SARS-CoV-2 vaccine dose versus no vaccination showed no clear Long COVID difference.
The vaccination estimate’s uncertainty range included no difference, which does not prove equality. The range of Long COVID percentages reflects the different definitions used.
Study details & original results
Cioni, Giovanni et al.. The Burden of Long-COVID-19 Among Pediatric Subjects: A Systematic Review and Meta-Analysis.. Journal of clinical medicine. 2026.
Pooled pediatric Long-COVID prevalence across 52 cohort studies; estimates varied from 16.2% under NIH criteria to 21.6% under WHO criteria, emphasizing dependence on the adopted definition.
18.1% 95% CI: 13.1-23.6
Likelihood of pediatric Long-COVID among individuals with at least one anti-SARS-CoV-2 vaccine dose versus unvaccinated individuals; the association was not statistically significant.
Omicron was linked to greater COVID-19 severity in children
295%higher relative odds
Compared with earlier variants, Omicron was linked to 295% higher relative odds of severe COVID-19 in children. Odds of moderate disease were also higher.
The featured number compares relative odds of severe disease, not a difference in actual risk. The study design and definitions of moderate and severe disease are not given here.
Study details & original results
Barter, Thomas T et al.. Impact of SARS-CoV-2 variants and demographic factors on COVID-19 severity in pediatric patients.. BMC infectious diseases. 2026.
Omicron variant associated with increased odds of severe COVID-19 disease compared to pre-Omicron variants in pediatric patients
OR 3.95 95% CI: 3.01-5.18
Omicron variant associated with increased odds of moderate COVID-19 disease compared to pre-Omicron variants in pediatric patients
OR 2.85 95% CI: 2.31-3.52
295% higher relative odds, calculated from OR 3.95. This is not an absolute percentage-point difference.
Long COVID was linked to worsening school performance in children
250%higher relative odds
Among infected children, those with long COVID had 250% higher relative odds of worsening school performance than those without it. Problems with daily functioning were separately recorded in 21% of infected children.
These health records show a link, not cause and effect. The featured number compares relative odds between groups, not the difference in actual risk. The 21% figure separately measures problems with daily functioning.
The source also reported behavior, mental health and school-support needs
Among children with Long COVID, higher odds were reported for new or worsening behavior or mental health symptoms and for needing school support.
The comparison groups are not given here, so the numerical odds are omitted.
Study details & original results
Case, Abigail et al.. Functional outcomes of children after SARS-CoV-2 infection: An EHR-based cohort study.. Journal of pediatric rehabilitation medicine. 2026.
School decline in children with long COVID vs. infected children without long COVID
OR 3.5 95% CI 1.6-7.9
Functional impairment documented among children with COVID-19 infection
21%
250% higher relative odds, calculated from OR 3.5. This is not an absolute percentage-point difference.
Bedir, Firat et al.. Post-acute symptom persistence following SARS-CoV-2, RSV, and influenza in children: A retrospective cohort study.. Medicine. 2026.
Significant virus-by-age interaction in post-acute symptom persistence, with the highest prevalence after RSV among infants and after SARS-CoV-2 among school-aged children.
Clinician-documented persistent symptoms 4-6 weeks after PCR-confirmed infection in children; overall prevalence did not differ significantly among the three viruses.
Di Chiara, Costanza et al.. SARS-CoV-2 Coinfections and Severity in Hospitalized Children With Systematic Testing.. The Pediatric infectious disease journal. 2026.
Respiratory viral coinfection was not associated with increased odds of severe COVID-19 among hospitalized children at centers with systematic multiplex PCR testing.
Zimmermann, Petra et al.. Comparison of Epidemiology, Risk Factors, Clinical Presentation and Outcomes of COVID-19 and Seasonal Influenza Among Hospitalized Swiss Children: A Nationwide Prospective Surveillance Study.. The Pediatric infectious disease journal. 2026.
Lobar pneumonia among hospitalized children with influenza; the abstract reports only an upper period-specific proportion and states that overall complications were more frequent with influenza (P < 0.001)
Cioni, Giovanni et al.. The Burden of Long-COVID-19 Among Pediatric Subjects: A Systematic Review and Meta-Analysis.. Journal of clinical medicine. 2026.
Pooled pediatric Long-COVID prevalence across 52 cohort studies; estimates varied from 16.2% under NIH criteria to 21.6% under WHO criteria, emphasizing dependence on the adopted definition.
Likelihood of pediatric Long-COVID among individuals with at least one anti-SARS-CoV-2 vaccine dose versus unvaccinated individuals; the association was not statistically significant.
Barter, Thomas T et al.. Impact of SARS-CoV-2 variants and demographic factors on COVID-19 severity in pediatric patients.. BMC infectious diseases. 2026.
Case, Abigail et al.. Functional outcomes of children after SARS-CoV-2 infection: An EHR-based cohort study.. Journal of pediatric rehabilitation medicine. 2026.
Browse the 15 original sourcesThe complete bibliography behind this monitor.
[1]
Case, Abigail et al.. Functional outcomes of children after SARS-CoV-2 infection: An EHR-based cohort study.. Journal of pediatric rehabilitation medicine. 2026.
Barter, Thomas T et al.. Impact of SARS-CoV-2 variants and demographic factors on COVID-19 severity in pediatric patients.. BMC infectious diseases. 2026.
Cioni, Giovanni et al.. The Burden of Long-COVID-19 Among Pediatric Subjects: A Systematic Review and Meta-Analysis.. Journal of clinical medicine. 2026.
Zimmermann, Petra et al.. Comparison of Epidemiology, Risk Factors, Clinical Presentation and Outcomes of COVID-19 and Seasonal Influenza Among Hospitalized Swiss Children: A Nationwide Prospective Surveillance Study.. The Pediatric infectious disease journal. 2026.
Di Chiara, Costanza et al.. SARS-CoV-2 Coinfections and Severity in Hospitalized Children With Systematic Testing.. The Pediatric infectious disease journal. 2026.
Bedir, Firat et al.. Post-acute symptom persistence following SARS-CoV-2, RSV, and influenza in children: A retrospective cohort study.. Medicine. 2026.
Flaxman S et al. Assessment of COVID-19 as the Underlying Cause of Death Among Children and Young People Aged 0 to 19 Years in the US. JAMA network open. 2023.
Block JP et al. Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022. MMWR. Morbidity and mortality weekly report. 2022.
Mandel H et al. Long COVID Incidence Proportion in Adults and Children Between 2020 and 2024: An Electronic Health Record-Based Study From the RECOVER Initiative. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2025.
Nugawela MD et al. Predicting post-COVID-19 condition in children and young people up to 24 months after a positive SARS-CoV-2 PCR-test: the CLoCk study. BMC medicine. 2024.
Cohen JM et al. Lower Risk of Multisystem Inflammatory Syndrome in Children With the Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023.
Irving SA et al. Effectiveness of 2024-2025 COVID-19 Vaccines in Children in the United States - VISION, August 29, 2024-September 2, 2025. MMWR. Morbidity and mortality weekly report. 2025.
Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results. Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed.
Download the findings and bibliography displayed in this page snapshot. Values and confidence intervals remain as reported text; this is not a pooled estimate or a systematic review. Product-label observations and editorial takeaways are excluded.
These findings may omit evidence or contain errors and have not been reviewed by a clinician. A citation or download does not establish source verification. Read the original studies for their methods and limitations.
The October 2026 COVID citation audit found errors in this collection. These downloads may still contain affected findings and bibliography entries. Read the correction record before using them.
“Added” dates record entry into the monitor, not publication or clinical review. A null original acquisition or derivation means its historical record is unknown; a current record or verification has its own observation time. The SHA-256 snapshot identifier binds the downloadable public fields. CSV includes finding rows and bibliography-only source rows; JSON includes both lists. Spreadsheet-sensitive CSV cells begin with an apostrophe for safety; JSON preserves the original text.
For attribution, cite ModernDoc and the page URL, data update date and snapshot identifier in the download. Original studies retain their own rights; this download does not grant a licence to their full text.